Study Overview: This research study is looking at a treatment called **NKX019**, which involves special immune cells called **CAR NK cells** targeting **CD19**. These cells are designed to help people with **lupus nephritis (LN)**, a kidney problem caused by lupus. The goal is to see if the treatment is safe and how well it is tolerated.
Key Details:
- **Target Group:** Participants must be 18 to 65 years old with active LN and have not improved with at least two other treatments.
- **Study Design:** The study has two parts and involves taking doses of NKX019 after a treatment to weaken the immune system. Participants will receive a three-dose cycle.
- **Exclusions:** People with severe kidney problems, certain infections, or other major health issues cannot participate.
Important Considerations:
- This study involves multiple visits and treatments over a period of time.
- Participants need to meet specific health criteria to join the study.
- Potential side effects and risks will be monitored throughout the study.
How understandable was the trial content above?
Hard to understand
Easy to understand